Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Respiratory Medicine Année : 2019

Dates et versions

hal-04526681 , version 1 (29-03-2024)

Identifiants

Citer

Marc Humbert, Frank Albers, Daniel Bratton, Steven Yancey, Mark Liu, et al.. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. Respiratory Medicine, 2019, 154, pp.69-75. ⟨10.1016/j.rmed.2019.06.004⟩. ⟨hal-04526681⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More